Skip to main content

Table 4 Risk factors associated with postoperative disease free survival and overall survival identified by multivariate Cox regression analysis

From: Perioperative blood transfusion has distinct postsurgical oncologic impact on patients with different stage of hepatocellular carcinoma

VariablesOSDFS
HR (95% CI)p-valueHR (95% CI)p-value
The entire cohort (n = 1255)
 Age, yr, ≤50 vs > 50  0.800 (0.688–0.931)0.004
 Cirrhosis, yes vs no  1.328 (1.117–1.578)0.001
 ALBI grade, 2 + 3 vs 11.225 (1.005–1.494)0.044  
 NLR, > 2.3 vs ≤ 2.31.080 (1.041–1.121)< 0.0011.034 (1.002–1.068)0.040
 Tumor size, cm, > 5 vs ≤ 51.437 (1.077–1.916)0.0141.311 (1.073–1.602)0.008
 Tumor no., multiple vs solitary1.489 (1.206–1.838)< 0.0011.583 (1.343–1.866)< 0.001
 Macro-VTT, yes vs no1.662 (1.288–2.143)< 0.0011.377 (1.126–1.685)0.002
 MVI, yes vs no1.581 (1.262–1.980)< 0.0011.541 (1.298–1.829)< 0.001
 AFP, μg/L, > 400 vs ≤ 4001.412 (1.154–1.726)0.0011.267 (1.086–1.477)0.003
 PBT, yes vs no1.623 (1.312–2.008)< 0.0011.365 (1.158–1.608)< 0.001
BCLC 0-A subgroup (n = 804)
 Age, yr, ≤50 vs > 50  0.986 (0.977–0.994)0.001
 Cirrhosis, yes vs no  1.325 (1.053–1.668)0.016
 ALBI grade, 2 + 3 vs 11.434 (1.094–1.879)0.009  
 NLR, > 2.3 vs ≤ 2.31.105 (1.056–1.157)< 0.0011.054 (1.010–1.099)0.016
 MVI, yes vs no1.643 (1.217–2.220)0.0011.578 (1.252–1.988)< 0.001
 AFP, μg/L, > 400 vs ≤ 4001.832 (1.390–2.413)< 0.0011.445 (1.167–1.789)0.001
 PBT, yes vs no1.756 (1.302–2.368)< 0.0011.607 (1.272–2.031)< 0.001
BCLC B-C subgroup (n = 451)
 Age, yr, ≤50 vs > 50  0.989 (0.980–0.999)0.025
 Tumor size, cm, > 5 vs ≤ 5  1.826 (1.151–2.897)0.011
 Tumor no., multiple vs solitary1.546 (1.129–2.116)0.007  
 PLR, > 118.9 vs ≤ 118.91.002 (1.000–1.003)0.013  
 MVI, yes vs no1.492 (1.059–2.102)0.0221.568 (1.253–1.961)< 0.001
 Macro-VTT, yes vs no2.033 (1.411–2.929)< 0.0011.367 (1.067–1.752)0.011
 Cirrhosis, yes vs no  1.408 (1.083–1.830)0.014
 PBT, yes vs no1.257 (0.929–1.700)0.1391.203 (0.950–1.525)0.126
  1. Abbreviation: OS overall survival, DFS disease free survival, HR hazard ratio, 95% CI 95% confident interval, ABLI grade albumin to bilirubin grade, NLR neutrophil to lymphocyte ratio, Macro-VTT macroscopic venous tumor thrombus, MVI microscopic vascular invasion, AFP alpha fetoprotein, PBT perioperative blood transfusion, PLR platelet to lymphocyte ratio